- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01234610
Feasibility Study of Exercise Training for Abdominal Aortic Aneurysm Disease
December 18, 2017 updated by: Sheffield Teaching Hospitals NHS Foundation Trust
Exercise Therapy for Abdominal Aortic Aneurysm Disease: a Feasibility Study
An abdominal aortic aneurysm (AAA) is a weakened and enlarged area in the abdominal aorta, which is a large blood vessel in the abdomen.
Large AAAs (>55 mm diameter) carry a high risk of rupture, a surgical emergency that often leads to death due to severe internal bleeding.
It has been suggested that regular exercise training might limit the rate at which AAAs develop.
However, little is known about the safety and effectiveness of exercise training in these patients.
This pilot study will examine the feasibility of supervised aerobic exercise training for patients with small AAAs (30 to 49 mm diameter).
The investigators hypothesize that exercise training will be safe and useful for patients with small AAAs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Abdominal aortic aneurysm (AAA) disease is a potentially lethal health problem of older adults.
New screening initiatives will identify many individuals with small (30 to 49 mm) AAAs for which there are currently no treatment options.
Regular aerobic exercise might retard AAA disease progression, but the feasibility and acceptability of aerobic exercise in patients with AAA disease has yet to be established.
This pilot study will examine the feasibility of supervised aerobic exercise and exercise advice-only in patients with small AAAs.
A total of 60 volunteers will be recruited and randomly allocated to one of the two groups.
Patients in the supervised exercise programme will be offered three supervised cycle ergometry/treadmill-walking sessions for a period of 12 weeks.
The feasibility of each intervention will be assessed in terms of recruitment and compliance, attrition, changes in cardiopulmonary fitness and objective measures of free-living physical activity.
Changes in aneurysm size and blood markers associated with disease progression will also be monitored and the impact of the interventions on health-related quality of life assessed using a questionnaire.
Outcomes will be assessed at baseline and 12 weeks.
We will also conduct focus groups at the end of the trial to obtain qualitative feedback from patients.
The results of this study will inform the design of a multi-centre randomised controlled trial with longer-term follow-up of clinical end-points.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S57AU
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Sheffield, South Yorkshire, United Kingdom, S102BP
- Sheffield Hallam University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men or women identified as having a stable 30 to 49 mm asymptomatic, infra-renal AAA, measured using high-resolution B-mode ultrasonography
- Ability to undertake exercise testing and training
Exclusion Criteria:
- Patients with large (>50 mm)/symptomatic AAAs
- Patients with contraindications to exercise testing/training (e.g. severe hypertension, unstable metabolic/cardiopulmonary conditions, musculoskeletal injuries etc…)
- Patients who are unable to travel to the testing and training facility at Sheffield Hallam University
- Patients who are already participating in regular exercise
- Patients with a mental impairment that would render consent unethical or would make compliance difficult (e.g. dementia or Alzheimer's)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
No exercise
|
|
Experimental: Exercise
|
Patients will be asked to attend three exercise sessions per week for 12 weeks.
They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist.
Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching.
The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility
Time Frame: 12 weeks
|
We will monitor how feasible it is to recruit, test and train patients with small AAAs
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiopulmonary fitness
Time Frame: 12 weeks
|
Peak oxygen uptake and ventilatory threshold assessed during an incremental-load cycling test
|
12 weeks
|
Quality of life
Time Frame: 12 weeks
|
Health-related quality of life assessed using the MOS SF-36 v2 questionaire
|
12 weeks
|
Aneurysm size
Time Frame: 12 weeks
|
Aneurysm size as measured using B-mode ultrasound
|
12 weeks
|
Blood biomarker of disease progression
Time Frame: 12 weeks
|
Fasting blood samples will be taken to assess changes in hs-CRP
|
12 weeks
|
Blood biomarker of disease progression
Time Frame: 12 weeks
|
Fasting blood samples will be taken to assess changes in MMP-9
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Garry A Tew, PhD, Sheffield Hallam University
- Principal Investigator: Shah Nawaz, MD, Sheffield Teaching Hospitals NHS Foundation Trust
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
November 3, 2010
First Submitted That Met QC Criteria
November 3, 2010
First Posted (Estimate)
November 4, 2010
Study Record Updates
Last Update Posted (Actual)
December 20, 2017
Last Update Submitted That Met QC Criteria
December 18, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH15455
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Supervised exercise training
-
University of ManchesterUnknownCardiovascular Diseases | Peripheral Arterial Disease
-
Medical University of ViennaUnknownPeripheral Artery DiseaseAustria
-
Chang Gung Memorial HospitalCompleted
-
Paracelsus Medical UniversityLudwig Boltzmann Institute for Digital Health and PreventionCompleted
-
Rigshospitalet, DenmarkUnknownIntermittent ClaudicationDenmark
-
University of Central ArkansasCompletedDiabetes Mellitus, Type 2United States
-
University of Colorado, DenverAmerican Diabetes AssociationCompleted
-
Université de SherbrookeCompleted
-
University of VermontCompletedCancer ThrombosisUnited States
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Failure, CongestiveUnited States, Canada, France